Image

Global Hypertriglyceridemia Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Hypertriglyceridemia Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Hypertriglyceridemia Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 10,162.59 USD Million
Diagram Market Size (Forecast Year) USD 14,552.10 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Hypertriglyceridemia Market, By Drug Class (Statins, Fibrates, Niacin, Omega-3 fatty acids, HMG-CoA reductase inhibitors), Type (Primary Hypertriglyceridemia, Secondary Hypertriglyceridemia, Others), Treatment (Pharmacological, Non-Pharmacological, Emerging Treatments, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Hypertriglyceridemia Market

Hypertriglyceridemia Market Analysis and Size

The global sialorrhea market is expected to witness significant growth during the forecast period. Approvals of drugs and product launches are projected to create much growth opportunities for market players operating in the global hypertriglyceridemia market. This increasing triglyceride levels are primarily associated with predisposing cardiovascular diseases and atherosclerosis, even in the absence of high cholesterol levels. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global hypertriglyceridemia market in the forecast period 2022-2029. The expected CAGR of global hypertriglyceridemia market is tend to be around 4.59% in the mentioned forecast period. The market was valued at USD 10162.59 million in 2021, and it would grow upto USD 14552.10 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hypertriglyceridemia Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug Class (Statins, Fibrates, Niacin, Omega-3 fatty acids, HMG-CoA reductase inhibitors), Type (Primary Hypertriglyceridemia, Secondary Hypertriglyceridemia, Others), Treatment (Pharmacological, Non-Pharmacological, Emerging Treatments, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare (U.K.), Wockhardt (India)

Market Opportunities

  • Growing Elderly Population
  • Increased R&D Activities

Market Definition

Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms of hypertriglyceridemia.

Global Hypertriglyceridemia Market Dynamics

Drivers

  • Increased Consumption of Unhealthy Diet

Higher consumption of unhealthy food and lifestyle is projected to expand the scope of growth of the global hypertriglyceridemia market. Increased demand for hypertriglyceridemia medications for use in the point-of-care healthcare sector to provide a solution for the requirement of preventive methods, is in return is, increasing the demand for this market.

  • Higher Drug Approvals

The growing number of drug approvals are anticipated to help companies build their market position. For instance, in December 2019, Amarin received FDA approval for VASCEPA (icosapent ethyl) which is indicated for reducing cardiovascular risk. The novel indication for VASCEPA is that it is an adjunct to diet to diminish triglyceride levels in aged patients with severe hypertriglyceridemia. This boosts the market growth.

Opportunities

  • Growing Elderly Population

Life expectancy is increasing all over the globe, which has led to an upsurge in the aging population. This trend positively impacts the industry by increasing the disease occurrence and creating per capita demand for its remedies. A rise in elderly visits to outpatient facilities and ambulatory surgery centers (ASC) results in the sound growth of the global hypertriglyceridemia market during the forecast period. Thus, it creates more opportunities for the market growth.

  • Increased R&D Activities

Major market players are investing to in development of novel drugs and launching these products in the market which in turn, is projected to significantly increase the market growth and create productive growth opportunities in the global hypertriglyceridemia market during the forecast period. For instance, in July 2019, Sun Pharma launched ‘Ezallor Sprinkle’ in the U.S. for people with difficulty swallowing. Ezallor Sprinkle capsules are indicated as an addition to the diet for the treatment of hypertriglyceridemia adult patient. It is also indicated for treating adult patients with type III hyperlipoproteinemi and other lipid-lowering treatments. These new treatment methods are creating more opportunities for the market.

 Restraints/Challenges

  • Lack of Medical Care

The lack of medical care in undeveloped economies may restrain the growth of hypertriglyceridemia market during the forecast period. Not much awareness leads to the unavailability of treatment and limits market growth.

  • High Cost

The huge expenditure associated with these therapeutics such as fibrates, niacin, omega-3 fatty acids hamper the market growth. The huge drug development and associated processes hamper the market's growth.

This global hypertriglyceridemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hypertriglyceridemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Covid-19 Impact on Global Hypertriglyceridemia Market

The hypertriglyceridemia market growth has been impacted majorly because of COVID-19 worldwide. According to EMCrit project, COVID-19 affected patients are more susceptible to having hypertriglyceridemia, primarily because of systemic inflammation. Therefore, ideally keeping the propofol dosages can help to maintain sedation and prevent conditions such as hypertriglyceridemia. It is difficult for several researchers and major market players to perform clinical trials during this pandemic crisis. However, in the post-pandemic era, numerous market players such as Eli Lilly and Company, and Pfizer are investing in research and development of novel hypertriglyceridemia drugs.

Global Hypertriglyceridemia Market Scope

The global hypertriglyceridemia market is segmented on the basis of type, drugs, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Primary Hypertriglyceridemia
  • Secondary Hypertriglyceridemia
  • Others

Drugs

  • Pharmacological
  • Non-Pharmacological
  • Emerging Treatments
  • Others

Drug class

  • Statins
  • Atorvastatin
  • Fluvastatin
  • Fibrates
  • Clofibrate
  • Fenofibrate
  • Niacin
  • Nicotinic acid
  • Nicotinamide
  • Omega-3 Fatty Acids
  • Alpha-linolenic acid (ALA)
  • HMG-CoA Reductase inhibitors
  • Altoprev
  • Amlodipine/atorvastatin.
  • Atorvastatin

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Hypertriglyceridemia Market Regional Analysis/Insights

The global hypertriglyceridemia market is analysed and market size insights and trends are provided by type, drugs, drug class, distribution channel and end-user as referenced above.

The major countries covered in the global hypertriglyceridemia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for global hypertriglyceridemia market throughout the forecasted period due to advanced healthcare facilities and the presence of multiple treatment options.

North America dominates the market due to increased public–private partnerships to promote R&D activities for treatment of sialorrhea in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hypertriglyceridemia Market Share Analysis

The global hypertriglyceridemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hypertriglyceridemia market.

Key players operating in the global hypertriglyceridemia market include:

  • Pfizer Inc (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Mylan N.V. (U.S.)
  • Fresenius Kabi AG (Germany)
  • Hikma Pharmaceuticals PLC (Japan)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol Myers Squibb Company (U.S.)
  • GSK Plc. (U.K.)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd (India)
  • Accord Healthcare (U.K.)
  • Wockhardt (India)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Hypertriglyceridemia Market will be worth USD 14552.10 million by 2029 during the forecast period.
The Hypertriglyceridemia Market growth rate is 4.59% during the forecast period.
Increased consumption of unhealthy diet & higher drug approvals are the growth drivers of the Hypertriglyceridemia Market.
The type, drugs, drug class, distribution channel and end-user are the factors on which the Hypertriglyceridemia Market research is based.
The major companies in the Hypertriglyceridemia Market are Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare (U.K.), Wockhardt (India)
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials